Large retrospective studies demonstrate that the risk for breast cancer is not elevated in people using GLP-1R agonists, particularly with follow-up of more than 2 years (21, 24, 79), nor is there excess risk for benign or premalignant breast neoplasms (21). Here, GLP1R is linked to breast cancer.